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Abstract
Background: Type-1 diabetes mellitus (DM) is a lifelong serious condition which often renders the application of
standard treatment options for patients' comorbid conditions, such as bipolar disorder I, risky – especially for acute
manic episodes. We present such a case whereby the application of standard anti-manic treatments would have
jeopardized a patient whose physical condition was already compromised by DM.
Methods: We report the case of a 55-year-old female with a history of type-1 DM since the age of 11, and severe ocular
and renal vascular complications thereof. While on the waiting list for pancreatic islet cell transplantation, she developed
a manic episode that proved recalcitrant to a treatment with gabapentin, lorazepam and quetiapine. Moreover, her
mental state affected adversely her already compromised glycemic control, requiring her psychiatric hospitalization. Her
psychotropic medication was almost discontinued and replaced by oxcarbazepine (OXC) up to 1800 mg/day for 10 days.
Results: The patient's mental state improved steadily and on discharge, 3 weeks later, she showed an impressive
improvement rate of over 70% on the YMRS. Moreover, she remains normothymic 6 months after discharge, with OXC
at 1200 mg/day.
Conclusion: Standard prescribing guidelines for acute mania recommend a combination of an antipsychotic with lithium
or, alternatively, a combination of an antipsychotic with valproate or carbamazepine. However, in our case,
administration of lithium was at least relatively contra-indicated because of patient's already compromised renal function.
Furthermore, antipsychotics increase glucose levels and thus were also relatively contra-indicated. Moreover, the
imminent post-transpantation immunosupressant treatment with immuno-modulating medicines also contra-indicated
both valproate and carbamazepine. Despite the severe methodological limitations of case reports in general, the present
one suggests that OXC as monotherapy might be both safe and efficacious in the treatment of acute mania in patients
with early-onset type-1 DM, whose already compromised physical condition constitutes an absolute or relative contra-
indication for the administration of standard treatments, though there are no, as yet, randomized clinical trials attesting
to its efficacy unambiguously.
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Background
Type-1 diabetes mellitus (DM) is a lifelong condition of
glycemic metabolism, with devastating and life-threaten-
ing systemic complications. Furthermore, the overall life-
long management of type-1 DM raises crucial issues of
patients' compliance to strict dietary and pharmacological
regimens as well as their capacity for resilience in the face
of chronic psychosocial stressors. Moreover, treatment
options of patients' comorbid conditions are often
restricted, as their side effects frequently threaten the
already compromised physical condition of the patients.
Nowadays an abundance of literature is available attesting
to both the strong relationship between bipolar disorder
(BPD) and type-2 DM [1,2] and the definite or likely
increased risk for the emergence of a metabolic syndrome,
including type-2 DM, in newly-diagnosed patients with
BPD treated with antipsychotics, especially atypical ones
[3]. However, to the best of our knowledge there are no
available studies or reports on safe and efficacious treat-
ment modalities for newly-diagnosed acute mania in
patients suffering from type-1 DM. In the present paper
we report on such a case, treated safely and effectively with
oxcarbazepine (OXC) as monotherapy.
Case presentation
The patient was a 55-year-old married female, mother of
two healthy grown-up children, with a history of type-1
DM since the age of 11. For her diabetes, she was initially
treated with insulin (Novolente) once and then twice
daily for 35 years. Subsequently, she was administered an
intensified insulin regimen comprising insulin (NPH)
twice daily and rapid-acting regular insulin three times
daily pre-prandially, followed by a regimen of NPH and
very-rapid acting insulin analogue (lispro) pre-prandially.
During the last 3 years the patient has been treated with
continuous subcutaneous insulin infusion through a
pump, requiring 18–20 units/day as a basal regimen and
a total of around 18–20 units/day as bolus injections.
However, during the last year, due to the patient's poor
compliance with the antidiabetic regimen and the
required dietary pattern, her glucemic control deteriorated
markedly, with frequent hypoglycemic episodes (and
even comas) 2–3 times a week, followed by hyperglyc-
emia events. In fact, the patient often felt hungry and, after
the extra meals and fearing that her glucose level had risen
excessively, she self-administered more insulin than
required, thus causing the hypoglycemic episodes. Over
the years she had also developed severe diabetic retinopa-
thy, requiring laser treatments, as well as renal vascular
complications of DM.
As a last resort to reverse this threatening situation her
treating physician decided to proceed to pancreatic islet
cell transplantation. Islet transplantation has been shown
to normalize metabolic control in a way that has been vir-
tually impossible to achieve with exogenous insulin [4]. A
thorough clinical and laboratory pre-transplantation
work-up was then performed, including CT and MRI brain
scans, which yielded minor findings for microvascular
brain disease. However, approximately 2 months later,
the patient underwent a significant change of mental state
with psychomotor restlessness, logorrhea and decreased
need for sleep. A thorough clinical and laboratory work-
up (including EEG and CT brain scan) was normal.
Alerted by the patient's markedly and abruptly changed
behavior and preoccupied by its impact on her already
aggravated glycemic control, her physician referred her to
a consultant in liaison psychiatry, who prescribed gabap-
entin up to 2 g/day and lorazepam 7.5 mg/day, without
adequate clinical response. Three weeks later, quetiapine,
up to 300 mg/day, was added to the patient's regimen. She
remained under this mixed anti-manic treatment for 2
months, again without satisfactory clinical response.
Moreover, the patient's persistently refractory mental state
adversely affected her already compromised glycemic con-
trol, requiring her psychiatric hospitalization. She was
highly reticent to this proposal, accepting it only reluc-
tantly on the advice of her treating physician.
On admission, the patient was excessively talkative and
exhibited pressured speech, flight of ideas, inflated self-
esteem, sexual disinhibition, psychomotor excitement
and increased energy with frenzied activity. Of note, no
signs of cognitive impairment as assessed by the Mini
Mental State Examination test [5] were detectable (score
on MMSE: 29). The patient was described as an always
lively person of hyperthymic temperament. However, no
discrete periods of elevated or depressed mood could be
traced in her history and she had never received mood-sta-
bilizing or other psychotropic agents previously. She was
diagnosed as having a manic episode according to DSM-
IV-TR diagnostic criteria [6]. On the Young Mania Rating
Scale (YMRS) [7] the patient initially scored 52. Her pre-
vious psychotropic medication was discontinued within
the first week, with the exception of small doses of
lorazepam, 1.5 mg/day, and replaced by OXC progres-
sively titrated to 1800 mg/day for 10 days. Nausea and
sedation were the only transitory side effects of OXC.
The patient's mental state under OXC improved steadily.
Initially, her psychomotor excitement subsided and her
sleep was normalized, followed by the submergence of
her remaining symptoms and signs. Three weeks later, on
discharge, her score on the YMRS had dropped to 15,
showing an impressive improvement rate of almost 71.2
%. In her weekly outpatient follow-up the patient remains
normothymic 8 months after discharge, again without
any signs of deterioration in her cognitive functioning. We
have already decreased OXC dosage progressively to 1200Annals of General Psychiatry 2007, 6:25 http://www.annals-general-psychiatry.com/content/6/1/25
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mg/day, and plan its long-term continuation as a mood
stabilizing treatment. Of note, the amelioration of her
mental state was accompanied by a stabilization of her
glycemic control, without any further hypoglycemic epi-
sodes. Likewise, regular laboratory investigations did not
reveal any hyponatremia, a rare though severe possible
side effect of OXC.
Discussion
According to both the American Psychiatric Association
[8] and the Maudsley prescribing guidelines [9], the
standard treatment of acute mania for patients with BPD
consists of a combination of an antipsychotic with lith-
ium salts or alternatively in a combination of an antipsy-
chotic with valproate or carbamazepine, possibly with a
benzodiazepine as an adjunctive medication. However, in
the case of our patient, administration of lithium salts was
relatively contra-indicated as an anti-manic agent and
clearly contra-indicated as a long-term mood stabilizer
because of their well known nephrotoxicity and our
patient's already mildly compromised renal function as a
diabetic complication. Furthermore, antipsychotics – not
only the atypical ones but even the respectively more safe
typical or classical antipsychotics such as haloperidol –
increase glucose level and were equally relatively contra-
indicated in our case (see, for example, [10]), with the
possible exception of ziprasidone, or aripiprazole [11].
Moreover, the imminent post-transplantation immuno-
supressant treatment of our patient with immuno-modu-
lating medicines also rendered the administration of both
valproate and carbamazepine (CBZ) as contra-indicated
because of the attendant increased risk for leucopenia or
even agranulocytosis. Besides, as has been shown in long-
term follow-up studies, islet transplants' function
decreases over time and thus, in order to maintain the
patients' insulin independence, repeated islet transplants
would have to be administered [4]. We submit that the
anti-manic treatment of our patient before her hospitali-
zation was far from adequate as gabapentin has not been
proved effective, especially in monotherapy. Moreover,
the dosage of quetiapine was clearly of the lowest limit of
its recommended range.
Furthermore, one cannot exclude the possibility that
patient's manic episode subsided spontaneously after an
almost 3 month course, though we consider this hypoth-
esis as rather implausible, given the unlikely event of the
mere temporal coincidence of her recovery with the inten-
sive inpatient treatment she underwent under OXC at a
dosage of 1800 mg/day. Moreover, one cannot exclude
the possibility that patient's loss of glycaemic control dur-
ing the year preceding her manic episode could have con-
tributed to its development. However, thereafter her
manic state clearly contributed to the further worsening of
her glycaemic control, through the loss of insight into the
severity of her physical condition. Likewise, the subse-
quent normalization of her mood contributed to the
recovery of her insight and the restoration of her compli-
ance to the anti-diabetic regimen. Finally, we could also
face the possibility that her manic episode could be the
clinical manifestation of an underlying microvascular
brain disease, as a complication of her 45 years of DM.
However, her unimpaired cognitive function, assessed
regularly over a 9-month period, jointly with the negative
findings from the CT and MRI scans, provides evidence
against the diagnostic hypothesis of secondary mania due
to a general medical condition.
The clinical efficacy of OXC, the 10-keto analogue of CBZ,
in the treatment of acute mania and hypomania is reason-
ably well documented in adults, but not in children and
adolescents [12-14], although there are as yet no large ran-
domized clinical trials attesting to its efficacy as a mood-
stabilizer [15,16]. However, extant studies suggest that
OXC could be effective as monotherapy or as adjunctive
therapy in almost 60% of patients with BPD [17-19].
OXC's mechanisms of therapeutic action, similarly to
those hypothesized for CBZ, could include its anticonvul-
sant properties and more precisely its enhancement of
GABA-ergic neurotransmission through its blocking
action on sodium and/or potassium channels [20],
although it seems highly doubtful that their mode of anti-
manic or more generally anti-bipolar action coincides
with their mode of anti-epileptic action. OXC is much
safer than CBZ, lacking the severe, though rare, hemato-
logic or hepatic adverse side effects of the latter. Rash,
somnolence, dizziness, headache, nausea, vomiting,
fatigue and usually asymptomatic hyponatremia are com-
mon, though benign with the exception of the latter, side
effects of OXC [21].
Conclusion
Despite the obvious severe limitations inherent to case
reports in general, the present work suggests that OXC as
monotherapy might be both safe and effective in the treat-
ment of acute mania in patients with early-onset type-1
DM, whose already compromised physical condition con-
stitutes an absolute or relative contra-indication to the
administration of standard treatments.
Competing interests
The authors have received support from various pharma-
ceutical companies in order to attend psychiatric or med-
ical congresses. However not from the manufacturer of
oxcarbazepine, Novartis,
Authors' contributions
PO made substantial contributions to conception and
design of the present study, and in the acquisition, analy-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Annals of General Psychiatry 2007, 6:25 http://www.annals-general-psychiatry.com/content/6/1/25
Page 4 of 4
(page number not for citation purposes)
sis and interpretation of the data. He was also involved in
drafting the manuscript and revising it critically for intel-
lectual content. He gave final approval for the manuscript
to be published. EK made substantial contributions to
conception and design of the present study, and in the
acquisition of data. AK made substantial contributions in
the analysis and interpretation of the data. He was also
involved in drafting the manuscript and revising it criti-
cally for intellectual content. VM made substantial contri-
butions to conception and design of the present study,
and in the acquisition, analysis and interpretation of the
data. He was also involved in drafting the manuscript and
revising it critically for intellectual content. He gave final
approval for the manuscript to be published. KK made
substantial contributions to conception and design of the
present study, and in the acquisition of data. KM made
substantial contributions in drafting the manuscript and
revising it critically for intellectual content. NAK made
substantial contributions to conception and design of the
present study, and in the acquisition of data. CP and NK
gave final approval for the manuscript to be published. CS
made substantial contributions in drafting the manuscript
and revising it critically for intellectual content. He gave
final approval for the manuscript to be published. All
authors read and approved the final manuscript.
Acknowledgements
The authors acknowledge the written consent for publication obtained 
from the patient featured in the manuscript.
References
1. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH: Bipolar disor-
der and diabetes mellitus: epidemiology, etiology, and treat-
ment implications.  Ann Clin Psychiatry 2005, 17:83-93.
2. Taylor V, MacQueen G: Associations between bipolar disorder
and metabolic syndrome: a review.  J Clin Psychiatry 2006,
67:1034-1041.
3. Guo JJ, Keck PE Jr, Corey-Lisle , Li H, Jiang D, Jang R, L'Italien GJ: Risk
of diabetes mellitus associated with atypical antipsychotic
use among patients with bipolar disorder: A retrospective,
population based, case-control study.  J Clin Psychiatry 2006,
67:1055-1061.
4. Lehman R, Pavlicek V, Spinos GA, Weber M: Islet transplantation
in type-1 diabetes mellitus.  Ther Umsch 2005, 62:481-486.
5. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state'. A prac-
tical method for grading the cognitive state of patients for
the clinician.  J Psychiatr Res 1975, 12:189-198.
6. American Psychiatric Association (APA): Diagnostic and Statistical Man-
ual of Mental Disorders 4 revised text edition. Washington DC: APA;
2000. 
7. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for
mania: reliability, validity and sensitivity.  Br J Psychiatry 1978,
133:429-435.
8. American Psychiatric Association (APA): APA Practice Guidelines for the
Treatment of Psychiatric Disorders – Compendium Washington DC: APA;
2006. 
9. Taylor D, Kerwin R, Paton : The Maudsley 2005–2006 Prescribing
Guidelines 8th edition. London: Taylor & Francis; 2006. 
10. Ramaswamy K, Masand PS, Nasrallah H: Do certain atypical antip-
sychotics increase the risk of diabetes? A critical review of 17
pharmacoepidemiologic studies.  Ann Clin Psychiatry 2005,
18(3):183-194.
11. Nasrallah HA, Newcomer JW: Atypical antipsychotics and met-
abolic dysregulation: evaluating the risk/benefit equation
and improving the standard of care.  J Clin Psychopharmacol 2004,
24(5 Suppl 1):S7-S14.
12. Hirschfeld RM, Kasper S: A review of the evidence for car-
bamazepine and oxcarbazepine in the treatment of bipolar
disorder.  Int J Neuropsychopharmacol 2004, 7(4):507-522.
13. Wagner KD, Kowatch RA, Emslie GJ, Findling RL, Wilens TE,
McCaque K: A double blind, randomized placebo-controlled
trial of oxcarbazepine in the treatment of bipolar disorder in
children and adolescents.  Am J Psychiatry 2006, 163:1179-1186.
14. Suppes T, Kelly DI, Hynan LS, Snow DE, Sureddi S, Foster B, Curley
E: Comparison of two anticonvulsants in a randomized, sin-
gle-blind treatment of hypomanic symptoms in patients with
bipolar disorder.  Aust N Z J Psychiatry 2007, 41(5):397-402.
15. Mazza M, Di Nikola M, Martinotti G, Taranto C, Pozzi G, Conte G,
Janiri L, Bria P, Mazza S: Oxcarbazepine in bipolar disorder: a
critical review of the literature.  Expert Opin Pharmacother 2007,
8(5):649-656.
16. Goodnick PJ: Anticonvulsants in the treatment of bipolar
mania.  Expert Opin Pharmacother 2006, 7(4):401-410.
17. Ghaemi SN, Berv DA, Klugman J, Rosenquist KJ, Hsu DJ: Oxcar-
bazepine treatment of bipolar disorder.  J Clin Psychiatry 2003,
64:943-945.
18. Benedetti A, Lattanzi L, Pini S, Musetti L, Dell'Osso L, Cassano GB:
Oxcarbazepine as add-on treatment in patients with bipolar
manic, mixed or depressive episode.  J Affect Dis 2004,
79:273-277.
19. Pratoomsri W, Yatham LN, Bond DJ, Lam RW, Sohn C: Oxcar-
bazepine in the treatment of bipolar disorder: a review.  Can
J Psychiatry 2006, 51:540-545.
20. White HS: Mechanism of action of newer anticonvulsants.  J
Clin Psychiatry 2003, 64:5-8.
21. Dunner DL: Safety and tolerability of emerging pharmacolog-
ical treatments for bipolar disorder.  Bipolar Disord 2005,
7:307-325.